Novartis Ag (NVS) Net Income (2009 - 2025)
Novartis Ag recorded quarterly Net Income of $4.5 billion in Q2 2025, down 34.99% quarter-over-quarter from $7.0 billion in Q4 2024, and up 17.96% year-over-year from $3.8 billion in Q2 2024.
Novartis Ag's Net Income history runs 17 years deep, the most recent figure standing at $4.5 billion for Q2 2025.
- In Q2 2025, Net Income rose 17.96% year-over-year to $4.5 billion; the TTM figure through Mar 2026 stood at $4.5 billion (down 58.09% YoY), while the FY2025 annual figure was $14.0 billion, up 16.99% from the prior year.
- Net Income came in at $4.5 billion for Q2 2025 at Novartis Ag, down from $7.0 billion in the prior quarter.
- In the past five years, Net Income ranged from a high of $7.0 billion in Q4 2024 to a low of $46.0 million in Q2 2023.
- A 5-year average of $2.3 billion and a median of $595.0 million in 2022 frame the typical range for Net Income.
- Across the five-year window, Net Income slumped 99.1% in 2023 and jumped 8250.0% in 2024, its largest moves.
- Novartis Ag's Net Income stood at $6.0 billion in 2021, then tumbled by 97.46% to $151.0 million in 2022, then advanced by 25.83% to $190.0 million in 2023, then jumped by 3568.42% to $7.0 billion in 2024, then sank by 34.99% to $4.5 billion in 2025.
- According to Business Quant data, Net Income over the past three periods registered $4.5 billion, $7.0 billion, and $3.8 billion for Q2 2025, Q4 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -13.00 Mn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 4.53 Bn |
| Dec 31, 2024 | 6.97 Bn |
| Jun 30, 2024 | 3.84 Bn |
| Dec 31, 2023 | 190.00 Mn |
| Sep 30, 2023 | 250.00 Mn |
| Jun 30, 2023 | 46.00 Mn |
| Mar 31, 2023 | 144.00 Mn |
| Dec 31, 2022 | 151.00 Mn |
| Sep 30, 2022 | 245.00 Mn |
| Jun 30, 2022 | 5.09 Bn |
| Mar 31, 2022 | 595.00 Mn |
| Dec 31, 2021 | 5.96 Bn |
| Sep 30, 2021 | 642.00 Mn |
| Jun 30, 2021 | 5.99 Bn |
| Mar 31, 2021 | 514.00 Mn |
| Dec 31, 2020 | 4.91 Bn |
| Sep 30, 2020 | 604.00 Mn |
| Jun 30, 2020 | 5.60 Bn |
| Mar 31, 2020 | 194.00 Mn |
| Mar 31, 2019 | -101.00 Mn |
| Dec 31, 2018 | -26.00 Mn |
| Sep 30, 2018 | -258.00 Mn |
| Jun 30, 2018 | 40.00 Mn |
| Mar 31, 2018 | 58.00 Mn |
| Dec 31, 2017 | 513.00 Mn |
| Sep 30, 2017 | 587.00 Mn |
| Jun 30, 2017 | 2.32 Bn |
| Mar 31, 2017 | 523.00 Mn |
| Dec 31, 2016 | 7.70 Bn |
| Sep 30, 2016 | 528.00 Mn |
| Jun 30, 2016 | 560.00 Mn |
| Mar 31, 2016 | 185.00 Mn |
| Dec 31, 2015 | 2.00 Mn |
| Sep 30, 2015 | 83.00 Mn |
| Jun 30, 2015 | -18.00 |
| Mar 31, 2015 | 519.00 |
| Dec 31, 2014 | -961.00 |
| Sep 30, 2014 | 138.00 |
| Jun 30, 2014 | -138.00 |
| Mar 31, 2014 | 514.00 |
| Sep 30, 2013 | 105.00 |
| Jun 30, 2013 | -39.00 |
| Sep 30, 2012 | 538.00 |
| Jun 30, 2012 | 602.00 |
| Mar 31, 2012 | 527.00 |
| Dec 31, 2011 | 999.00 |
| Sep 30, 2011 | 539.00 |
| Jun 30, 2011 | 561.00 |
| Mar 31, 2011 | 713.00 |
| Dec 31, 2010 | 504.00 |
| Sep 30, 2010 | 618.00 |
| Jun 30, 2010 | 469.00 |
| Mar 31, 2010 | 3,530.00 |
| Dec 31, 2009 | 12.14 Bn |
| Sep 30, 2009 | 2,491.00 |
| Jun 30, 2009 | 2,443.00 |
| Mar 31, 2009 | 2,296.00 |